Pharmacologic Substance – Page 3

FDA Advisory Panel Rejects GSK’s Blenrep in New Combinations Over Safety, Efficacy Concerns

1 week ago talkbio0Tagged Advisory Panel, Blenrep, concerns, DREAMM, Drug Approval, Multiple Myeloma, Ocular Toxicity, Refractory Plasma Cell Myeloma, Relapsing course, Safety, SmithKline Beecham, trials, United States Food and Drug Administration

Blenrep; GSK; FDA Advisory Panel; multiple myeloma; ocular toxicity; safety concerns; DREAMM trials; drug approval; relapsed or refractory multiple myeloma

Kowa Secures Expanded Rights to Nicox’s Glaucoma Drug NCX 470 in Major Global Deal

1 week ago talkbio0Tagged Clinical Trials, Denali, Glaucoma, Kowa, licensing agreement, milestone payments, naproxen-n-butyl nitrate, Ophthalmology specialty, royalties, TLX2 gene

Kowa; Nicox; NCX 470; glaucoma; exclusive rights; licensing agreement; Denali clinical trial; ophthalmology; royalties; milestone payments

Bristol Myers Squibb and Pfizer Launch Direct-to-Consumer Discount Program for Eliquis

1 week ago talkbio0Tagged Anticoagulants, blood thinner, Direct-to-Consumer, Eliquis, Myers, online program, Pfizer, squibb

Bristol Myers Squibb; Pfizer; Eliquis; direct-to-consumer; discount; online program; Eliquis 360 Support; anticoagulant; blood thinner; patient access

Sarepta Shifts Focus to siRNA Platform, Lays Off 500 After Elevidys Receives Black Box Warning

1 week ago talkbio0Tagged acute liver injury, black box, Cautionary Warning, ELEVIDYS, gene therapy, layoffs, Muscular Dystrophy, Duchenne, pipeline shift, restructuring, RNA, Small Interfering

Sarepta Therapeutics; siRNA platform; Elevidys; Duchenne muscular dystrophy; layoffs; black box warning; pipeline shift; acute liver injury; gene therapy; restructuring

AstraZeneca Amyloidosis Drug Fails Phase 3 Trials but Shows Potential in Subgroup

1 week ago talkbio0Tagged Alexion, Amyloidosis, Anselamimab, AstraZeneca, Clinical trial failure, Drug Development, Infrequent, prespecified, Primary amyloidosis, Subgroup A Nepoviruses

AstraZeneca; amyloidosis; anselamimab; Phase 3 trial; clinical trial failure; prespecified subgroup; rare diseases; Alexion; AL amyloidosis; drug development

J&J’s Stelara Revenue Plummets as Biosimilar Competition Intensifies in 2025

1 week ago talkbio0Tagged Autoimmune Diseases, Benefit, Biosimilars, drug price, formulary exclusion, Johnson & Johnson, manager, Pharmaceutical Services, Revenue Decline, Stelara, ustekinumab

Stelara; Johnson & Johnson; ustekinumab; biosimilars; revenue decline; Q2 2025; pharmacy benefit managers; formulary exclusion; drug pricing; autoimmune disease

Sino Biopharm Acquires Merck’s PD-1xVEGF Bispecific Partner LaNova for up to $951M

2 weeks ago talkbio0Tagged Acquisition, Antibodies, Bispecific, Biopharm, Cancer Therapeutic Procedure, isononanoyl oxybenzene sulfonate, LaNova Medicines, Merck, PD-1xVEGF

Sino Biopharm; LaNova Medicines; acquisition; Merck; PD-1xVEGF bispecific antibody; cancer therapy; Chinese pharma; $951 million deal

Veru Survey Highlights Muscle Loss Concerns Among GLP-1 Users as Lean Mass-Preserving Drug Advances

2 weeks ago talkbio0Tagged agonists, Diet, High-Protein, Elderly (population group), enobosarm, GLP-1 receptor, Lean Mass, muscle loss, Obesity, Surveys, Veru

Veru; GLP-1 receptor agonists; muscle loss; enobosarm; lean mass; obesity; survey; older adults; high-protein diet

FDA Flags Eye Safety Concerns as GSK Seeks Blenrep’s US Return

2 weeks ago talkbio0Tagged Advisory Committees, Blenrep, Drug Approval, Eye, Eye safety, Multiple Myeloma, relapsed/refractory multiple myeloma, SmithKline Beecham, Toxicity aspects, United States, United States Food and Drug Administration

GSK; Blenrep; FDA; eye safety; ocular toxicity; advisory committee; multiple myeloma; drug approval; United States; relapsed/refractory multiple myeloma

LEO Pharma Acquires Exclusive Global Rights for Boehringer Ingelheim’s Psoriasis Drug Spevigo in €90 Million Deal

2 weeks ago talkbio0Tagged Boehringer Ingelheim, Drug licensing, Generalized pustular psoriasis, IL1RAP protein, human, Immunology, News [Publication Type], Partnership, Pharma, Psoriasis, spesolimab, Spevigo

LEO Pharma; Boehringer Ingelheim; Spevigo; spesolimab; psoriasis; GPP; drug licensing; immunology; IL-36 receptor; partnership; biotech news